Pfizer Drug Xeljanz Has Managed To Succeed Clinical Trails

Xeljanz drug for rheumatoid arthritis by Pfizer has managed to pass the clinical trials and tests in ulcerative colitis.

Pfizer Inc. has managed to pass clinical tests for its arthritis drug in ulcerative colitis making the pathway for another approval for the oral medication.  The data that has been gathered from these studies is going to be used in the application to regulators for approval of UC for xeljanz (tofacitinib).

The two studies were from oral clinical trials at the 11th Congress of ECCO from OCTAVE induction 1 and OCTAVE induction 2, for the tests and analysis of safety and efficiency of the drug in 10 mg per day for adult patients who have ulcerative colitis. Xeljanz was seen to reduce moderate to severe UC and was showing better results than placebo. The pharmaceutical company conducted a test in which patients were being given 10 mg of xeljanz twice every day which proved to be successful in no rectal bleeding in just eight week as compared to 8.2% of individual who were given a placebo.

Pfizer Inc. might be able to provide patients with a better and more efficient treatment.  This disease is difficult to handle leading most of the patients either becoming completely intolerant to any treatment whatsoever. The patients given xeljanz showed improvement and mucosal healing. The tests were conducted on patients’ injected with biotech medications before and even the ones who did not receive any treatment before.

Millions of patients around the world are diagnosed with UC, which affects the bowels with symptoms like abdomen pain, weight loss, diarrhea and many other painful health issues.   Xeljanz has the approval of 45 countries worldwide proving its success in 6,200 patients, who were diagnosed with moderate RA.  

The pharmaceutical giant consistently provides its customers with drug and medication that did not exist before. It has received many approvals for treatments of cancer and now UC. Xeljanz might be good for patients suffering from UC, but it can increase the risk of certain types of cancer as it changes the manner, the immune systems functions including Lymphoma, skin cancer. Patients who are considering taking this medication should first know what problems they have, and should consult a doctor before start taking it. 

Xeljanz is going to serve patients with psoriatic arthritis, especially for the ones on whom DMARDs do not work and even the ones who don’t show good response on the usual anti-TNF treatment. For now, the drug is undergoing FDA review. This drug can become the top seller of the company; it managed to gain sales worth $523 million in 2015 with a 70% increase in comparison to 2014.